JMP Securities initiated coverage on Summit Therapeutics Inc. (NASDAQ:SMMT), noting the company’s initial focus on infectious ...

Now this is a fine way to begin a week on the stock market. Summit Therapeutics (NASDAQ: SMMT) saw its stock price rise ...

Fintel reports that on November 4, 2024, JMP Securities initiated coverage of Summit Therapeutics (NasdaqGM:SMMT) with a ...

This year, Summit Therapeutics Inc. (SMMT) leads the parade of winners among large stocks (those with a market value of $10 billion or more).

Now this is a fine way to begin a week on the stock market. Summit Therapeutics (NASDAQ: SMMT) saw its stock price rise notably Monday, on the happy news that an analyst has initiated coverage ...

In terms of valuation, Summit Therapeutics Inc’s market capitalization stands at $14.71 billion. Market cap represents the total value of all outstanding shares and is a key indicator of a company’s ...

Biopharma stocks are rarely suitable for short-term investing, so hold onto them. Summit Therapeutics may have a powerful new ...

Summit Therapeutics targets potential $17.9 billion in peak revenue in NSCLC market by 2034. JMP Securities initiated coverage on Summit Therapeutics Inc. SMMT, noting the company’s initial ...

The 6th RNAi-Based Therapeutics Summit is returning to Boston in January 2025 with fresh insights and perspectives.

Eric Volkman has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Summit Therapeutics. The Motley Fool has a disclosure policy.